[In Italy] we have the full pharma and life science value chain from the early start of research to the manufacturing and selling of drugs ...…
In Conversation
The pandemic revealed the importance of having assets like our plant within the European territory. The most important thing for Reig Jofre is ... the fact…
Aristo differentiates itself in the market through its dynamism and its ability to move quickly and diversify its business ... the company will soon move into…
... 60-70 percent of current Italian needs are covered self-sufficiently. In Italy plasma is for the Italians’ needs and not to be sold to other countries.…
Within reproductive medicine we are the leaders in the Italian market and one of the top 10 markets worldwide, still we want to be higher in…
Over the past ten years, our growth has been 100 percent organic, fuelled by Accord-developed products and in-licensing and underpinned by a very committed, enthusiastic and…
Organon took a portfolio of more than 60 products, 9,000+ employees and over USD 6 billion in revenue; it is a large and complex organization that…
... our R&D department, which is big and growing, participates in 80 percent of MSD’s global clinical trials, making the affiliate number one in Europe by…
AIFA has always favoured innovation and, in this context, has defined specific criteria with the aim of guaranteeing quick access to medicines that have a clear…
The Spanish biosimilars industry is experiencing a reduction of prices, regulatory changes regarding product approval, and increased local and global competition, which is a complex topic…
... we excel in supply chain, keeping in mind that our model is B2B; our success relies on delivering products on time so that clients can…
The technical and economic advantage of using zebrafish is due to the ability to study multiple organisms in a reduced space.
